64Cu-ATSM

DRUG3 trials

Sponsors

Narita Yoshitaka, American College of Radiology, Institut Cancerologie de l'Ouest

Conditions

Cervical CancerMalignant glioma glioblastoma, grade3/4 astrocytoma, grade3 oligodendrogliomaRectal Cancer

Phase 2

Phase II Trial of 64Cu-ATSM PET/CT in Cervical Cancer

TerminatedNCT00794339

American College of RadiologyCervical Cancer

Start: 2009-07-29End: 2011-12-31Updated: 2023-08-14

64Cu-ATSM PET/CT in Rectum Cancer (TEP 64Cu-ATSM-Rectum)

Active, not recruitingNCT03951337

Institut Cancerologie de l'OuestRectal Cancer

Start: 2019-04-26End: 2026-01-31Target: 70Updated: 2024-03-12

Phase 3

NCCH2301 (STEP-64 trial)

RecruitingJPRN-jRCT2031240090

Narita YoshitakaMalignant glioma glioblastoma, grade3/4 astrocytoma, grade3 oligodendroglioma

Start: 2024-05-01Target: 56Updated: 2025-07-18

Related Papers

Efficacy of radioactive hypoxia-targeting therapeutic agent 64Cu-ATSM on recurrent malignant glioma: a study protocol for a phase-III, investigator-sponsored, randomized controlled trial

Japanese Journal of Clinical Oncology2025-02-272 citations

Pilot study of PET imaging of 124I-iodoazomycin galactopyranoside (IAZGP), a putative hypoxia imaging agent, in patients with colorectal cancer and head and neck cancer.

2013-06-0310 citations